- Home
- BJDX vs PRFX Comparison
BJDX vs PRFX Comparison
Compare BJDX & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJDX | PRFX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BJDX | PRFX |
|---|---|---|
| Price | $2.00 | $2.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.9K | ★ 169.9K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $249,040.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $0.58 |
| 52 Week High | $10.20 | $3.71 |
Technical Indicators
Market Signals| Indicator | BJDX | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 59.53 |
| Support Level | $1.43 | $1.28 |
| Resistance Level | $2.47 | $3.65 |
| Average True Range (ATR) | 0.16 | 0.25 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 48.98 | 37.16 |
Price Performance
Historical ComparisonAbout BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.